A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation

Key Inclusion Criteria: * Have signed the informed consent form and the HIPAA patient information form (United States only) * Are ≥ 18 years of age * Are a transplant recipient of at least one HLA-mismatch kidney * For subjects of reproductive potential (men and women), are willing to use effective contraception, unless abstinence is the chosen method Key Exclusion Criteria: * Have a history of previous renal transplant * Have had a PRA \> 25% at any time * Have a history of or evidence of cancer except for basal cell carcinoma that has been excised and cervical carcinoma in situ * Have a positive T-cell lymphocytotoxic crossmatch with the use of donor lymphocytes and recipient serum * Have had previous treatment with efalizumab * Have used any investigational drug within 28 days or 5 half-lives of screening, whichever is longer * Have a known contraindication to efalizumab * Have a history of severe allergic or anaphylactic reactions to monoclonal antibodies * Have had a known allergic reaction or intolerance to any of the following medications: CsA; MMF; Corticosteroids; Basiliximab * Are allergic to iodinated contrast media that would preclude GFR measurement with iothalamate